MYRIAD GENETICS INC. overview

BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD PR Newswire SALT LAKE CITY, Sept. 28, 2023 SALT LAKE CITY , Sept. 28, 2023 /PRNewswire/ -- A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast density and family health history are two misunderstood breast cancer risk factors. Experience the full interactive Multichannel News Release here:...

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States PR Newswire SAN DIEGO, March 2, 2023 Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry SAN DIEGO , March 2, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision...

Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay. More than one million Vectra tests have been completed since the product’s launch in November 2010, and a meaningful portion of testing volume currently flows through Labcorp. “Labcorp has...

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that the Shareholder Class Action Against Myriad Genetics, Inc. (NASDAQ: MYGN) has survived the motions to dismiss in the pending securities class action and may face damages. Long-term investors are encouraged to contact the firm. According to the securities class action complaint, throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business,...

Thinking about buying stock in Aurora Cannabis, Cytokinetics, Quotient, Myriad Genetics, or Avaya Holdings? PR Newswire NEW YORK, May 11, 2020 NEW YORK , May 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, CYTK, QTNT, MYGN, and AVYA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ACB:...

The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN ). The investigation relates to possible breaches of fiduciary duty by certain officers and directors of the Company. In July 2019, the Company paid $9.1 million to resolve claims brought by a whistleblower that formed the basis for a subpoena issued by the U.S. Department of Health and Human Services Office of Inspector General to the Company in...

...